SAN DIEGO, Oct. 6, 2015 /PRNewswire/ -- MEI Pharma,
Inc. (Nasdaq: MEIP), an oncology company focused on the clinical
development of novel therapies for cancer, today announced that
data from the Company's Phase II clinical studies of Pracinostat in
elderly acute myeloid leukemia (AML) and previously untreated
myelodysplastic syndrome (MDS) have been selected by the American
Society of Hematology (ASH) Program Committee for oral presentation
at the 57th ASH Annual Meeting & Exposition in Orlando on December 7,
2015.
Final Results from a Phase 2 Study of Pracinostat in
Combination with Azacitidine in Elderly Patients with Acute Myeloid
Leukemia (AML)
Abstract: 453
Session: 613. Acute Myeloid Leukemia: Clinical Studies: Advances in
Therapy
Presentation: Monday, December 7,
2015 at 7:30 am Eastern
time
A Randomized, Placebo-Controlled, Phase II Study of
Pracinostat in Combination with Azacitidine (AZA) in Patients with
Previously Untreated Myelodysplastic Syndrome
(MDS)
Abstract: 911
Session: 637. Myelodysplastic Syndromes – Clinical Studies I
Presentation: Monday, December 7,
2015 at 7:15 pm Eastern
time
Abstracts are expected to be available at www.hematology.org on
Thursday, November 5, 2015 at
9:00 am Eastern time. In addition,
the abstracts will be published online in the December 3, 2015 supplemental volume of
Blood.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on
the clinical development of novel therapies for cancer. The
Company's portfolio of drug candidates includes Pracinostat, a
potential best-in-class, oral HDAC inhibitor currently in Phase II
studies for advanced hematologic diseases, including AML, MDS and
myelofibrosis. The Company is also developing ME-344, a novel
mitochondrial inhibitor that has shown evidence of clinical
activity in refractory solid tumors. In addition, the Company is
completing a first-in-human study of PWT143, a highly selective,
oral PI3K delta inhibitor. For more information, please visit
www.meipharma.com.
Under U.S. law, a new drug cannot be marketed until it has
been investigated in clinical studies and approved by the FDA as
being safe and effective for the intended use. Statements included
in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties or differences in interpretation in
clinical trial results; our inability to maintain or enter into,
and the risks resulting from our dependence upon, collaboration or
contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our
patents or proprietary rights and obtain necessary rights to third
party patents and intellectual property to operate our business;
our inability to operate our business without infringing the
patents and proprietary rights of others; general economic
conditions; the failure of any products to gain market acceptance;
our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry
practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions
to these forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20140805/133834
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mei-pharma-announces-data-from-phase-ii-clinical-studies-of-pracinostat-accepted-for-oral-presentation-at-american-society-of-hematology-annual-meeting-300154700.html
SOURCE MEI Pharma, Inc.